Id-1 Gene and Gene Products as Therapeutic Targets for Treatment of Breast Cancer and Other Types of Carcinoma

ABSTRACT

A method for treatment of breast cancer and other types of cancer. The method comprises targeting and modulating Id-1 gene expression, if any, for the Id-1 gene, or gene products in breast or other epithelial cancers in a patient by delivering products that modulate Id-1 gene expression. When expressed, Id-1 gene is a prognostic indicator that cancer cells are invasive and metastatic.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. patent application Ser. No.12/326,832, filed on Dec. 2, 2008, currently pending, which is adivisional of U.S. patent application Ser. No. 11/390,682, filed on Mar.27, 2006, currently allowed, which is a continuation of U.S. patentapplication Ser. No. 09/952,534, filed on Sep. 14, 2001, now issued asU.S. Pat. No. 7,429,047, issued on Sep. 30, 2008, based on and claimingpriority of the Provisional application Ser. Nos.: 60/232,529 and60/232,558, both filed on Sep. 14, 2000, the contents of all which areincorporated herein by reference in their entirety.

STATEMENT OF GOVERNMENTAL SUPPORT

This invention was made with government support under Contract No.DE-AC03-765F00098, now Contract No. DE-AC02-05CH11231, awarded by theUnited States Department of Energy, and under NIH Grant for NCIRO1CA82548. The Government has certain rights in this invention.

REFERENCE TO ATTACHED SEQUENCE LISTING

This application incorporates by reference the attached sequence listingfound in paper and electronic form.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention concerns a diagnosis, prognosis and treatment ofbreast, endometrium, cervical, ovarian, squamous cell, prostate andmelanoma cancer. Particularly, the invention concerns the use of Id-1and/or Id-2 genes or Id-1 and/or Id-2 products as diagnostic markers forcancer cells metastatic agressivity and use of detection of the Id-1 orId-2 genes, or a ratio thereof, or use of detection of the Id-1 or Id-2products, or a ratio thereof, for diagnosis and prognosis of breastcancer. The invention further concerns a method for treatment of breastcancer by targeting Id-1 or Id-2 genes, or a combination thereof,through delivery of antisense transcripts, ribozymes, smalltherapeutically active molecules, drugs, peptides or organic compoundsthat disrupt Id-1 protein interaction with bHLH transcription factor orenhance Id-2 action with bHLH transcription factor and vice versa, RNA,anti-Id4 RNAi causing degradation of homologous Id-1 mRNAs, Id-2 as agene or a protein, or ITF-2 as a gene or protein, or targeting Id-1 orId-2 proteins with antibodies or with compounds which either enhance orimpair their expression thereby affecting the feedback of the geneexpression. The invention further concerns the detection of Id-1 or Id-2products or genes or their ratio with a kit comprising anti Id-1 and/orId-2 antibodies or Id-1 or Id-2 probes.

2. Description of Related Art

Breast cancer is one of the most common malignancies among women andshares, together with lung carcinoma, the highest fatality rate of allcancers affecting females.

There are very few diagnostic markers available for breast cancerdetection and those which are available have a predictive accuracy onlyabout twenty percent. There is no marker available that can detect ordetermine cancer cells metastatic agressivity.

The current treatment of the breast cancer is limited to a veryinvasive, total or partial mastectomy, radiation therapy, orchemotherapy, later two resulting in serious undesirable side effects.

It would thus be desirable to have available additional new diagnosticmethods which would detect the presence of cancer with greater accuracyand which would permit determination of distinction of highly aggressivebreast cancer cells having a tendency to metastasize from the cancercells which remain localized and have low probability of metastaticspread. It would also be desirable to have available methods for lessinvasive treatment of the breast or other cancers.

The mammary gland is one of the few organs that undergo strikingmorphological and functional changes during adult life, particularlyduring pregnancy, lactation, and involution.

When normal epithelial breast cells become transformed, a number ofgenetic alteration occur which lead to tumorigenesis and metastasis.These alterations affect growth control, maintenance of differentiatedepithelial functions and invasiveness. Identifying the genes involved inthese processes is essential for understanding how breast cancerdevelops, and for deriving better methods for prognosis and treatment.

In both humans and mice, fetal virgin adult, and pregnant mammary glandsundergo extensive temporal, structural and spatial remodeling, whichentails invasion, migration, and relocation of cells to generate theductal and alveolar structures of the gland. Once lactation isterminated, there is additional and extensive tissue remodeling as thegland returns to its resting state.

During each menstrual cycle, and especially during pregnancy, lactationand involution, mammary epithelial cells go through cycles ofproliferation, invasion, differentiation and apoptotic cell-death. Themechanisms that regulate these complex and developmentally coordinatedcell phenotypes are only poorly understood. However, at least some ofthe downstream genes that are regulated during these different stages ofmammary development have been identified.

In recent years, some progress has been also made in elucidating themechanisms that regulate mammary gland-specific gene expression and thetransformation of mammary epithelial cells to malignancy. However, thepractical use of these findings for detection, prognosis and treatmentof cancer and its malignant propensities has not been described.

It is, therefore, a primary objective of this invention to provide amethod and means for detection and prognosis of breast cancer, fordetermination of the malignant agressivity of cancer cells and forproviding therapeutically effective agents for suppression and therapyof breast, endometrium, cervical, ovarian, squamous cells and prostatecancer and melanoma.

All patents, patent applications and publications cited herein arehereby incorporated by reference.

SUMMARY OF THE INVENTION

One aspect of the current invention is a method for diagnosis, prognosisand treatment of breast, cervical, ovarian, endometrium, squamous,prostate and melanoma cancer. Another aspect of the current invention isthe use of Id-1 and/or Id-2 genes as diagnostic markers for metastaticagressivity of breast, cervical, ovarian, endometrium and squamouscancer cells.

Yet another aspect of the current invention is the use of Id-1 and/orId-2 proteins as diagnostic markers for metastatic agressivity ofprostate and melanoma cancer cells.

Still another aspect of the current invention is a method for detectionof the Id-1 or Id-2 genes, or a ratio thereof, or for detection of theId-1 or Id-2 products, or a ratio thereof, as the markers for diagnosisand prognosis of breast cancer.

Still yet another aspect of the current invention is a method fortreatment of breast cancer and other types of cancer by targeting Id-1and/or Id-2 genes, or a combination thereof, through a delivery ofantisense transcripts, ribozymes, small therapeutically activemolecules, drugs, peptides or organic compounds that disrupt Id-1interaction with a bHLH transcription factor or enhance Id-2 proteinaction with a bHLH transcription factor, RNA, anti-Id4 RNAi causingdegradation of homologous Id-1 mRNAs, Id-2 as a gene or a protein, orITF-2 gene or protein.

Yet another aspect of the current invention is a kit for detection ofId-1 or Id-2 genes or Id-1 or Id-2 products, or their ratio, said kitcomprising anti Id-1 and/or Id-2 antibodies or anti Id-1 and/or Id-1probes.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a Northern blot showing a pattern of Id-1 and Id-2 expressionin the mouse mammary gland.

FIG. 2 is a Northern mRNA blot of Id-1 expression in cultured breastcancer cells that were either growing in 10% serum (G) or incubated inserum-free medium (SF).

FIG. 3 is a Western analysis using a polyclonal antibody against humanId-1 protein with cross-reactive bands around M_(R) 40,000 (40 Kda)indicating loading and transfer efficiency with nine cell clones ofT47D-Id-1.

FIG. 4 is a graphical representation of Boyden Chamber invasion assayfor T47D-Id-1 cell clones.

FIG. 5 is an autoradiogram of T47D cells incubated with [³H]thymidine.

FIG. 6A is a Western analysis of an Id-1 protein expression probed withthe Id-1 antibody in non-invasive cancer T47D (lane 1) and metastaticcancer MDA-MB-231 (lane 2) cells. The position of Id-1 protein isindicated. FIG. 6B is an immunohistogram wherein panels (a), (b), and(c) are representative sections from ductal carcinomas in situ (DCIS),and panels (d), (e), and (f) are Grade 3 invasive carcinomas analyzed byimmunohistochemistry with anti Id-1 anti-serum.

FIG. 7 is a Northern blot showing Id-2 mRNA expression in human breastcancer cell lines cultured in serum-free medium for two days.

FIG. 8 is a Western analysis showing inverse correlation between Id-1and Id-2 protein expression in growing (G) and differentiated (Diff)mouse mammary SCp2 epithelial cells in culture.

FIG. 9 is a Northern mRNA analysis showing an inverse correlationbetween Id-1 and Id-2 mRNA expression in growing (G), serum starved(SSt) and laminin-treated mouse mammary SCp2 cells in culture for 24 and48 hours.

FIG. 10A shows reduction of casein expression in mammary epithelialcells treated with Id-2 antisense oligonucleotides. FIG. 10B showsincrease of casein expression in mammary epithelial cells infected witha LXSN-Id-2-sense and Id-2-antisense expression vectors.

FIG. 11 is a Northern mRNA analysis displaying a different pattern ofexpression in the mouse mammary gland in vivo at different stages ofdevelopment wherein V indicates virgin, P indicates pregnant and Lindicates lactation stage. Northern analysis was performed using cDNAprobes for mouse.casein, Id-1 and Id-2.

FIG. 12A is a Northern analysis of Id-1 and Id-2 mRNA expression inhuman breast cancer cell lines. Cell were cultured in serum-free mediumfor 48 hours before RNA was extracted. Lane 1: T47D; lane 2: MCF-7; lane3: MDA-MB-231 and lane 4: MDA-MB-436 cell lines. FIG. 12B shows Id-1 andId-2 expression in MCF-7 growing in 10% FBS (lane 1) and MCF-7 culturedin serum-free medium for 24 hours (lane 2).

FIG. 13 is a Western blot showing Id-1 protein expression. Lane 1 showsMDA-MB436 controls, lane 2 shows MDA-MB436 Id-1 sense infected with anamphotropic retrovirus and lane 3 shows MDA-MB436 Id-1 antisenseinfected with an amphotropic retrovirus.

FIG. 14 is graphical illustration of FIG. 13 showing a conversion ofaggressive MDA436 cells into non-aggressive cells when treated with Id-1antisense amphotropic retrovirus in an in vitro invasion assay.

FIG. 15 is a graph showing decrease in tumor number in 4T1/BalbC micetreated with various constructs in vivo.

FIG. 16 (a-b) is a print out from the NCBI, and sets forth Accession No.X77956 (definition, “Homo sapiens Id-1 mRNA”), and provides H. sapiensId-1 gene and Id-1 protein encoded thereby.

FIG. 17 (a-b) is a print out from the NCBI, and sets forth Accession No.D13891 (definition, “Human mRNA for Id-2H, complete cds”), and providesH. sapiens Id-2 gene and Id-2 protein encoded thereby.

DEFINITIONS

As used herein:

“Id” means inhibition of differentiation or DNA binding.

“Id proteins” means proteins which are inhibitors of differentiation orDNA binding.

Since Id proteins function by binding basic helix-loop-helix (bHLH)transcription factors, Id-1- or Id-2-interacting proteins are importanttranscriptional regulators of mammary epithelial cell properties.

“Id-1” means protein expressed by Id-1 gene. High levels of Id-1 proteinare expressed by aggressive and metastatic breast, cervical, ovarian,endometrium and squamous cancer cells. High levels of Id-1 protein areexpressed in noninvasive prostate cancer and melanoma.

“Id-2” means protein expressed by Id-2 gene. Increased levels of Id-2protein are crucial for normal breast development. Breast, cervical,endometrium and squamous cancer cells producing high level of Id-2protein are less invasive. Increased levels of Id-2 protein areexpressed by highly invasive and metastatic prostate cancer cells.

“Id-1-interacting proteins” are proteins which interact with Id-1protein. These proteins are, therefore, important transcriptionalregulators of mammary epithelial cell properties.

“ITF-2” is a bHLH transcription factor which interacts with Id-1 and is,therefore, an example of Id-1 interacting protein. ITF-2 appears to beconstitutively expressed in SCp2 epithelial cells. Although Id-1expression fluctuates during mammary epithelial cell growth anddifferentiation, the expression of ITF-2, determined by ITF-2 mRNA, insuch proliferating and differentiating SCp2 cells, does not fluctuate.The mouse ITF-2 (mITF-2) insert was found to contain a 950 bp openreading frame encoding the bHLH and C-terminal domains of ITF-2, butmissing the N-terminal region.

“HLH” means helix-loop-helix.

“bHLH” means basic helix-loop-helix.

“GAPDH” means glyceraldehyde-3-phosphate dehydrogenase.

“DAPI” means 4′,6-diamidino-2-phenylindole.

“DCIS” means ductal carcinoma in situ.

“EGR” means early growth.

“Gene product” means a protein or mRNA.

“RNAi” means RNA interference process for a sequence-specificpost-transcriptional gene silencing of a gene by providing adouble-stranded RNA (dsRNA) that is homologous in sequence to thesilenced gene. Small interfering RNAs (siRNAs) generated by ribonucleaseIII cleavage from longer dsRNA are the mediators of sequence-specificmRNA degradation.

DETAILED DESCRIPTION OF THE INVENTION

The current invention is based on findings that Id-1 and Id-2 genes areinvolved in tumor progression of breast, cervical, ovarian, endometrium,squamous cells and prostate carcinoma and melanoma and that Id-1 andId-2 genes are involved in the development of breast cancer and are,therefore, suitable to serve as diagnostic markers and therapeutictargets for these types of cancer.

Specifically, it has been discovered that Id-1 gene is involved in andplays a critical role in the development of a proliferative and invasivephenotype in breast, cervical, endometrium and squamous epithelial cellsand that it is constitutively expressed in the least differentiated andhighly aggressive human cancer cells and that Id-2 gene is involved indevelopment of a less aggressive or non-aggressive phenotype in thesecancer cells.

The Id-2 gene, on the other hand is involved in the development of aproliferative and invasive phenotype in prostate cancer cells, whereId-1 gene seems to play just the opposite role, that is, it is involvedin the development of a less aggressive or nonaggressive phenotype andprostate and melanoma cancer cells.

It has been further discovered that both Id-1 and Id-2 genes, Id-1 andId-2 proteins, and their respective ratios, may be convenientlydetected.

Additionally, the invention is based on findings that both Id-1 and Id-2genes expression may be effectively suppressed or at least decreased bythe targeted conversion with amphotropic retrovirus carrying Id-1 orId-2 antisense.

Consequently, the invention concerns, in its broadest scope, adiagnosis, prognosis and treatment of breast, endometrial, cervical,ovarian, squamous cells or prostate carcinoma or melanoma.

I. Function of Id-1 and Id-2 Genes and Breast Cancer

Aggressive breast cancer cells that are metastasizing to other parts ofthe body have been known to loose a specific regulation of the geneinvolved in normal breast cell development. By contrast, normallydeveloping breast cells maintain this regulation. Little is known,however, about the transcriptional regulators that control theexpression of these developmental stage-specific genes.

Basic helix-loop-helix (bHLH) transcription factors are key regulatorsof lineage- and tissue-specific gene expression in a number of mammalianand non-mammalian organisms. These transcription factors bind DNA ashomo- or heterodimers, and activate the transcription of target genescontaining E-boxes or E-box-like sequences in their promoters.Dimerization occurs through the HLH domains, whereas DNA binding occursthrough the two basic domains.

Id proteins, which are inhibitors of differentiation or DNA binding, arehelix-loop-helix (HLH) proteins that lack a basic domain. Id proteinsact as dominant inhibitors of bHLH transcription factors by formingtranscriptionally inactive heterodimers.

So far, four Id genes (Id-1 through Id-4) have been identified. Thesegenes, although similar in their organization and HLH sequences,localize to different chromosomes and show differences in their patternof expression and function. For example, the cytogenetic location ofId-1 protein is 20q11, whereas location of Id-2 is 2p25, location ofId-3 is 1p36.13-p36.12 and location of Id-4 is 6p22-p21.

The helix-loop-helix protein Id-1 has been shown to inhibit the activityof basic helix-loop-helix transcription factors, and is an importantregulator of cell growth and tissue-specific differentiation.

These findings led inventors to investigate a possible correlationbetween the levels of Id-1 protein and the aggressiveness of humanbreast cancer cells leading to the current discovery.

A. Id-1 and Id-2 Gene DNA Sequences

Nucleotide sequences of human Id-1 and Id-2 genes are known and havebeen deposited at GenBank under Accession numbers D13891 and X77956,respectively. Nucleotide sequence which is a source for Id-1 genecomprises of 926 nucleotides with an Id-1 gene encoding region startingat nucleotide 36 and ending at nucleotide 500. Nucleotide sequence whichis a source for Id-2 gene comprises of 1049 nucleotides with Id-2 genecoding region starting at nucleotide 97 and ending at nucleotide 501.

B. Function of Id-1 and Id-2 Genes

It has been now discovered that Id-1 and Id-2 genes function as negativeregulators of helix-loop-helix (bHLH) transcription factors playing acritical role in the development of a proliferative and invasivephenotype. Such function of Id-1 and Id-2 genes was not previouslyknown.

During the development of the current invention the ectopic expressionof the Id-1 gene has been found to inhibit differentiation and stimulatethe proliferation and invasiveness of mammary epithelial cells.

The expression of Id-2 gene, on the other hand, has been found to beup-regulated during differentiation of mammary epithelial cells and itsexpression increased in the differentiated human breast cancer cells.Such up-regulation of Id-2 expression was found to be a necessary steptoward a fully differentiated phenotype in breast cells.

Compared to expression of Id-1, expression of Id-2 was found to be muchhigher in the differentiated human breast cells than the expression ofthe very aggressive and metastatic cells leading to conclusion thatthere may be a correlation between the levels of Id-1 or Id-2 proteinsand the aggressiveness or non-aggressiveness in human breast cancercells.

The Id-1 and Id-2 protein levels change dramatically at different stagesof breast development. An increase in the level of Id-2 protein iscrucial for normal breast development. In breast cancer cells, thecancer cells producing high levels of Id-2 protein are less invasive. Bycontrast, aggressive and metastatic breast cancer cells express highlevel of Id-1 mRNA and Id-1 protein.

C. Experimental Evidence and Studies

The evidence supporting the above described findings is based on studiesperformed on murine epithelial cell lines, on normal mouse mammaryglands in vivo, on human breast cancer cells and on human breast cancerbiopsies.

1. Effect of Manipulating Id-1 Expression on Differentiation of MurineMammary Epithelial SCp2 Cell Phenotypes

SCp2 cells, a cell line developed from murine mammary gland, are auseful model system for studying mammary epithelial cell growth anddifferentiation in cell culture.

A role of Id genes in the normal differentiation of SCp2 cells was firstsuggested by inventors prior findings that Id-1 expression declinedrapidly to undetectable levels when the cells differentiated in responseto lactogenic hormones, such as insulin, prolactin and hydrocortisoneand upon contact with basement membrane (Mol. Cell. Biol., 15:3398-3404(1995).

To directly test the role of Id-1 in these cells, the cells weretransfected with an expressible murine Id-1 gene, in either the sense orantisense orientation.

In monolayer culture and low serum medium, Id-1 sense cells grew fasterthan control cells transfected with the vector lacking a cDNA insert. Bycontrast, Id-1 antisense cells grew more slowly than controls. Both Id-1sense and Id-1 antisense cells ceased growth and formed aggregates orspheres when provided with basement membrane and lactogenic hormones.However, Id-1 sense cells formed spheres that were less compact thanspheres formed by controls or antisense expressing cells, and failed toexpress the milk protein β-casein. Under the same conditions, Id-1antisense cells expressed β-casein at a higher level than control cells.

Despite differences in β-casein expression, control, Id-1 sense and Id-1antisense cells exposed to hormones and basement membrane remained agrowth arrested for 5 to 6 days. After 8-10 days, however, spheres ofId-1 sense cells began to disintegrate as individual cells dissociatedfrom the sphere, began to invade the basement membrane and resumedgrowth. In the Boyden Chamber invasion assay, Id-1 sense cells were muchmore invasive than normal SCp2 or Id-1 antisense cells. The Id-1 sensecells, unlike control or Id-1 antisense cells, expressed a gelatinase ofapproximately 120 kDa. The activity of this gelatinase was specificallyinhibited by inhibitors of matrix-metalloproteinases.

Id-1 protein expression in the nontransformed SCp2 cells resulted in aloss of cell-cell interaction, loss of ability to express markers ofdifferentiation and in an increased ability to invade a basementmembrane, migrate and proliferate.

All these propensities make the cells expressing constitutively highlevels of Id-1 protein most highly aggressive and metastatic.

2. The Role of Id-1 in Normal Mammary Gland Development In Vivo

The role of Id-1 in normal mammary gland was determined by following theexpression of Id-1 during normal mouse mammary gland development invivo, using Northern analysis of total RNA from virgin (V), pregnant (P;days 2 to 18), and lactating (L) mice. Result are shown in FIG. 1.

FIG. 1 is a Northern analysis of total RNA extracted from mouse mammarygland at different stages of development. Northern analysis utilizedcDNA probes for mouse.casein, Id-1 and Id-2 gene expression.

As seen in FIG. 1, .casein mRNA was evident only during mid and latepregnancy and lactation. When the blot was reprobed with Id-1 cDNA, Id-1expression was found to be inversely correlated with casein expression,confirming the role of Id-1 gene in vivo observed in the SCp2 cells.

These results clearly show that Id-1 expression declines when themammary gland proceeds toward full differentiation during pregnancy andat the lactation stage. Id-1 thus is expressed primarily in cells whichare nondifferentiated or begin to differentiate.

3. Analysis of Id-1 Expression in Human Breast Cancer Cell lines andBreast Biopsies

Findings that ectopic Id-1 expression induced an invasive phenotype inmouse mammary epithelial cells suggested that Id-1 gene could contributeto human breast cancer progression.

To begin to explore this possibility, human breast cancer cell linesexhibiting varying degrees of invasiveness in culture and in vivo, usingmetastatic tumor formation in nude mice, was examined. Results of thesestudies show that highly aggressive human breast cells have lost theirserum regulation of Id-1 gene expression. Results are shown in FIGS.2-6.

The regulation of Id-1 gene expression in the presence of serum wasexamined in non-invasive cancer T47D and MCF-7 cell lines and inaggressive and invasive cancer MDA-MB-231 and MDA-MB-435 cell lines. Thefirst two are noninvasive human breast cancer cell lines, the latter twoare highly invasive metastatic cells which were selected for a highlyaggressive phenotype by passage in immunodeficient mice. All cells werepurchased from the American Tissue Culture Collection (ATCC).

In some cells, Id-1 gene expression is known to be induced by certainmitogens, such as, for example, serum. Consequently, the effect of thepresence or absence of serum on expression of Id-1 gene in these twotypes of cells was investigated. RNA was isolated from both types ofcells that were grown on either 10% serum (G) or incubated in serum-freemedium (SF). RNA was then analyzed by Northern analysis according toExample 3. Results are seen in FIG. 2.

FIG. 2 illustrates a loss of serum-regulated Id-1 expression inaggressive breast cancer cells. Upper panel shows a position of Id-1mRNA (1.2 kb). Lower panel shows a position of the ribosomal 28S RNAused as control for RNA integrity and quantitating.

As seen in FIG. 2, T47D and MCF-7 non-invasive cancer cells expressedhigh levels of Id-1 mRNA only when cultured in serum. When cultured inserum-free medium for two days, such expression levels wereundetectable. In contrast, highly aggressive and metastatic MDA-MB-231and MDA-MB-435 cells constitutively expressed Id-1 mRNA, regardless ofthe presence or absence of serum.

These results show that in non-invasive breast cancer cell, theexpression of Id-1 gene could be induced by culturing these cells in thepresence of serum. However, in these non-invasive breast cancer cells,this gene was not expressed and the expression could not be induced inserum-free medium. On the contrary, the invasive metastatic cancer cellsexpressed Id-1 gene in both the serum containing and serum-free medium.Consequently, the invasive metastatic breast cancer cells do not needId-1 expression induction by serum but it is in their cellular make-upto express Id-1 gene constitutively.

4. Constitutive Id-1 Expression Converts a Nonaggressive into a MoreAggressive Breast Cancer Cell Line

To test whether the unregulated Id-1 expression contributes toaggressive phenotype of human breast cancer cells and to determine ifthe induced constitutive Id-1 expression would convert nonaggressivecells into aggressive metastatic cells, constitutive Id-1 expression wasinvestigated.

For this purpose, the human Id-1 cDNA was expressed in nonaggressiveT47D cells using amphotropic retrovirus (pBabe-Id-1). Production ofpBabe-Id-1 retroviral vector and virus are described in Example 1.Retroviral infection is described in Example 2. Puromycin was used toselect virus-expressing cells.

Briefly, approximately eight RT-units of either pBabe-puro or pBabe-Id-1retrovirus were mixed with 5 ml of medium containing 4 μg/ml polybreneand were added to T47D cells in 100-mm dishes. Cells expressing theretroviral genes were selected in 0.6 μg/ml puromycin, which killed allof the mock-infected cells within three days, whereas 80 or 30% of thepBabe-puro or pBabe-Id-1-infected cells, respectively, survived. Thepuromycin-resistant cells are referred to as T47D-pBO or T47D-Id-1. Toestablish single-cell clones, the T47D-Id-1 population was plated at 1-2cells/well in 24-well tissue LXSN retroviral vector was prepared in thesame way except neomycin was used to select virus expressing cellsculture plates. Clones that grew in the wells were expanded. Results areseen in FIG. 3.

FIG. 3 illustrates Id-1 protein levels obtained in nine clones. WhenT47D cells were infected with pBabe-Id-1 retrovirus, ninesingle-cell-derived clones (clone 1-clone 9) were obtained. The cloneswere cultured in serum-free medium for two days before proteinextraction and Western analysis using a polyclonal antibody againsthuman Id-1. Positions of Id-1 protein and molecular weight markers ineach clone are indicated. Cross-reactive bands around M_(r) 40,000 (40kDa) indicate loading and transfer efficiency.

From nine single-cell-derived clones isolated from the T47D-Id-1population, the clone 6 was lost during processing. Each of the eightsurviving clones expressed a different level of Id-1 protein, asdetermined by Western analysis. Clones 1, 2, and 8 expressed relativelyhigh levels of Id-1 protein in serum-free medium, whereas clones 4 and 9expressed very low levels of Id-1 under these conditions. The otherclones expressed Id-1 at intermediate levels.

Five T47D-Id-1 clones, expressing either high or low levels of Id-1 inserum-free medium, were then examined for invasiveness using the BoydenChamber invasion assay. Conditions of the Boyden Chamber invasion assayare described in Example 5. Results are shown in FIG. 4.

FIG. 4 illustrates Boyden Chamber invasion assay for T47D clones. Cellswere cultured in serum-free medium for 2 days before they were placed inthe upper chamber of Matrigel-coated trans-well filters. The invasionassay was carried out for 20 hours in serum-free medium and cells thatmigrated through the filter were stained and counted. Results wereaveraged and SDs were calculated.

As seen in FIG. 4, the invasive activity of each clone was approximatelyproportional to the level of Id-1 protein expression. Thus, clones withconstitutively high levels of Id-1 (clones 1, 2, and 8) were moreinvasive then clones expressing low levels of Id-1 protein (clones 4 and9). The invasive activity of the low-expressing clones resembled that ofthe uninfected parental T47D cells (not shown).

Ectopic Id-1 expression also conferred a growth advantage in serum-freemedium, as measured by the percentage of cells incorporating[³H]-thymidine. Conditions of the [³H]-thymidine labeling are describedin Example 6. Results are seen in FIG. 5.

FIG. 5 shows percentage of labeled nuclei of cells cultured inserum-free medium for 32 hours before incubation with [³H]-thymidine foradditional 16 hours and processed by autoradiography. Cell thatincorporated [³H]-thymidine were calculated as a percentage of totalDAPI-stained nuclei.

As seen in FIG. 5, the three T47D-Id-1 clones that expressed Id-1proteins at higher levels had a greater [³H]-thymidine-labeling indexthan two clones in which Id-1 expression was lower. The three T47D-Id-1clones that expressed Id-1 protein at higher levels had a greaterthymidine-labeling index than two clones in which expression of Id-1protein was lower. Thymidine-labeling index for clones 1, 2 and 8 was59%/average, for clones 4 and 9 it was 36%/average.

These results show that when normal Id-1 regulation is lost and Id-1 isconstitutively expressed, human breast cancer cell lines acquireincreased invasiveness and a proliferative advantage in a growthfactor-deficient media. Ectopic Id-1 expression converted a relativelynonaggressive breast cancer cell line into a relatively aggressive one.

These results show that by determining a level of Id-1 proteinexpression, evaluation of the breast cells agressivity can be made.

Since the above findings indicated that Id-1 expression may serve as aprognostic marker for certain subset of aggressive breast cancers,breast cancer biopsies for Id-1 expression were further examined byimmunohistochemistry.

5. Id-1 Expression in Breast Cancer Biopsies

To determine whether the above obtained observations are applicable tohumans, a large number of breast cancer biopsies were obtained frompatients and immunohistochemical reactions as well as Western analyseswere performed.

Immunohistochemical determination of the expression of Id-1 protein wascarried out on a total of eighty-three breast cancer biopsies obtainedfrom patients treated at California Pacific Medical Center.

Twenty-three of the biopsies were ductal carcinoma in situ (DCIS), sixtybiopsies were infiltrating carcinomas of which twelve were Grade 1,seven were Grade 2 and forty-one were of Grade 3 carcinoma.

Out of twenty-three ductal carcinomas in situ (DCIS), 18 were foundnegative (78%), three were weakly positive (13%), and two were stronglypositive (9%). Infiltrating carcinomas Grade 1, which is the leastaggressive amongst the invasive tumors, displayed a pattern of Id-1protein expression similar to the DCIS. Out of twelve Grade 1 carcinoma,10 were negative (83%), 1 was weakly positive (8.5%), and 1 was stronglypositive (8.5%). On the other hand, the majority of the infiltratingGrade 2 and Grade 3 carcinomas, the most aggressive tumors, were weaklyor strongly Id-1 positive. Out of seven Grade 2 carcinomas, 3 werenegative, 1 was weakly positive, and 3 were strongly positive. Out offorty-one Grade 3 carcinomas, 16 were negative (39%), 4 were weaklypositive (10%), and 21 were strongly positive (51%).

Results are seen in Table 1.

TABLE 1 Id-1Protein Expression Determined By Immunohistochemistry in 83Breast Cancer Biopsies Id-1 Id-1 Weakly Id-1 Strongly Tumor TypeNegative Positive Positive Ductal Carcinoma in Situ 78% (18/23) 13%(3/23)  9% (2/23) Infiltrating Carcinoma Grade 1 83% (10/12) 8.5%(1/12)  8.5% (1/12)  Grade 2 43% (3/7)  14% (1/7)  43% (3/7)  Grade 339% (16/41) 10% (4/41)  51% (21/41)

Numbers in parenthesis indicate the actual number of biopsies out of thetotal number of biopsies examined.

Results of six selected representative samples in this assay are seen inFIGS. 6A and 6B which show expression of Id-1 in human breast cancerbiopsies. Immunohistochemistry was carried out using a specific batch ofanti-Id-1 antibody, confirmed by Western analysis to show nocross-reactive bands. Immunohistochemical procedure is described inExample 8.

FIG. 6A is a Western analysis showing the specificity of the Id-1antibody used for immunohistochemistry. Lane 1 shows non-invasive T47Dcancer cells, lane 2 shows invasive and metastatic MDA-MB-231 cancercells. All cells were cultured in serum-free medium for 48 hours.Position of Id-1 protein is indicated. No cross-reactive band is seen.Results shown in FIG. 6A clearly confirm high expression of Id-1 proteinin the cancer cells when compared to Id-1 expression in T47D cells.

FIG. 6B shows representative section from DCIS (panels a, b, and c) andGrade 3 invasive carcinoma (panels d, e and f) which were analyzed byimmunohistochemistry using antiserum against Id-1 protein. The majorityof DCIS were negative (panels a and b), one showed strong positivity inits large ductal structure (panel c). The majority of infiltratingcarcinoma, on the other hand, showed strong Id-1 immunoreactivity (paneld and e). Minority of the invasive tumors were negative (panel f). Inpanel d, a differentiated glandular section, the structure with thelumen was negative whereas infiltrating cells showed strongimmunoreactivity.

These results show that almost all examined ductal carcinomas in situ(DCIS) were negative for Id-1 staining. However, the majority (51%) ofinfiltrating Grade 3 carcinomas of ductal origin were strongly Id-1positive. These results confirm that Id-1 is a reliable prognosticmarker for breast cancer invasiveness and metastatic propensity.

6. Expression of Id-2 in Human Breast Cancer Cells

To determine if the expression of Id-1 protein was specific toaggressive malignant cancer cells or if this was common property of Idproteins, the expression of the second Id protein, namely Id-2 protein,in human breast cancer cells was examined.

Id-2 expression in human cancer cells was determined by Northernanalysis. The same four types of cells were used as used previously instudies with Id-1. These cells were cultured in serum-free medium fortwo days before RNA was extracted. The blot was hybridized with a humanId-2 cDNA probe. Results are shown in FIG. 7.

FIG. 7 is a Northern analysis of Id-2 transcripts. Upper panel showsexpression of Id-2 mRNA in non-invasive T47D (lane 1) and MCF7 (lane 2)cancer cells and in highly aggressive, metastatic and invasiveMDA-MB-231 (lane 3) and MDA-MB436 (lane 4) cancer cells. Lower twopanels show a positions of two ribosomal 28S and 18S RNA used as controlfor RNA integrity.

FIG. 7 shows that under the same experimental conditions as thosedescribed for Id-1, Id-2 mRNA was found to be expressed in lanes 1 and2, which correlate with non-invasive T47D and the MCF7 human breastcancer cell lines. As seen in FIG. 7, lanes 3 and 4, there was nodetectable Id-2 mRNA in lanes 3 or 4, which represent highly invasiveMDA-MB-231 and MDA-MB-436 human breast cancer cell lines.

Thus, in contrast to Id-1, the expression of Id-2 gene products, such asthe protein and mRNA, correlates with non-aggressive or non-invasivecancers.

These results show that both Id-1 and Id-2 are fair indicators of breastcancer presence and agressivity and that each indicates and is found ina different type of cancer cells. Detection of Id-1 expression indicatespresence of highly aggressive, metastatic and invasive cancer cells.Detection of Id-2 expression indicates presence of noninvasive cancercells.

7. Inverse Correlation between Id-1 and Id-2 Expression

A direct regulatory link has been found to exist between Id-1 and Id-2genes in breast cells. Id-2 protein expression is generally high whenId-1 protein expression is low, both in vitro and in vivo, confirming anexistence of a negative correlation in expression levels.

a. Id-2 Expression In Vitro

To determine the pattern of Id-2 expression during mammary cell growthand differentiation, expression of Id-2 protein during mammaryepithelial cell differentiation in vitro and in vivo was undertaken.

For this purpose, the yeast two-hybrid system and the basichelix-loop-helix protein ITF-2 as a bait were used to isolate Id-2 froma library derived from differentiated, milk-producing mammary epithelialcells. First, Id-2 protein expression in SCp2 cells during proliferationor differentiation was investigated, using Western analysis. Results areshown in FIG. 8.

FIG. 8 is a Western analysis showing inverse correlation between Id-1and Id-2 protein expression in growing (G) and differentiated (Diff)SCp2 mammary epithelial cells treated with Matrigel and lactogenichormones for 48 and 72 hours. Protein was extracted and analyzed usingantibodies specific for Id-1, Id-2 and .casein milk protein, which isthe marker for mammary epithelial cells differentiation.

As shown in FIG. 8, differentiated cells expressed high levels of theId-2 (16 kDa) protein, similarly to expression of casein, at both 48 and72 hours. In comparison, Id-1 protein was detectable only inproliferating cells (lane G). No expression of Id-1 protein was detectedin differentiated cells. These results clearly show that there is aninverse correlation between Id-1 and Id-2 protein.

To confirm this inverse correlation between Id-1 and Id-2 expression,Northern analysis of SCp2 cells proliferating or treated with lamininfor 24 and 48 hrs was performed. Laminin is an important component ofextracellular matrix and can trigger differentiation. Results are seenin FIG. 9.

FIG. 9 is a Northern analysis of inverse correlation between Id-1 andId-2 mRNA expression in growing (G), serum starved (SSt), andLaminin-treated SCp2 mammary epithelial cells for 24 and 48 hours. TotalRNA was extracted and analyzed using probes specific for Id-1, Id-2 andcasein.

Results seen in FIG. 9 confirm results seen in FIG. 8. There wasexpression of both Id-2 and casein in differentiated cells, but therewas no expression of Id-1 in these cells. Id-1 was expressed only ingrowing (G) cells confirming that the inverse correlation exists betweenexpression of Id-1 and Id-2 mRNA.

In order to determine if Id-2 up-regulation was a crucial event formammary epithelial cell differentiation and milk production, two sets ofexperiments were performed. In the first set, SCp2 cells were treatedwith Laminin and lactogenic hormones for 48 hrs in the presence ofeither control oligonucleotides or Id-2 antisense oligonucleotides.Results are seen in FIG. 10.

FIG. 10A illustrates reduction of casein expression in mammaryepithelial cells treated with Id-2 antisense oligonucleotides. Lane 1shows SCp2 cells treated with Laminin for 48 hours and controloligonucleotide. Lane 2 shows Scp2 cells treated with Laminin for 48hours and with Id-2 oligonucleotide. FIG. 10B illustrates increase ofcasein expression in mammary epithelial cells infected with a LXSN-Id-2sense expression vector (Lane 2) and inhibition of casein expression incells infected with a LXSN-Id-2 antisense expression vector (Lane3).Lane 1 corresponds to cells infected with a LXSN-control vector.

As seen in FIG. 10A, a dramatic reduction of β-casein expression wasobserved in Id-2 antisense oligonucleotide treated cells. In the secondset of experiments, SCp2 cells were infected with either LXSN-control,LXSN-Id2-sense or LXSN-Id2-antisense constructs, selected with neomycinand treated with laminin for 48 hrs. As shown in FIG. 10B, β-caseinexpression was increased in SCp2-LXSN-Id2-sense cells in comparison tocontrol. Most dramatically, β-casein expression was almost undetectablein SCp2-LXSN-Id2-antisense cells.

The results seen in FIGS. 10A and 10B show that Id-2 is involved andnecessary in and its up-regulation occurs during mammary celldifferentiation. However, the results in FIG. 10B also shows that suchup-regulating can be effectively negated with Id-2 antisense carryingconstruct.

b. Id-2 Expression In Vivo

To determine Id-2 protein expression in vivo and to compare it to theexpression of Id-1 protein, another set of experiments was performed.

In these studies, the level of Id-1 and Id-2 mRNA during mammary glanddevelopment in vivo, using Northern analyses of total RNA from virgins,pregnant and lactating mice were determined. Results are seen in FIG.11.

FIG. 11 shows a different pattern of Id-1 and Id-2 protein expression inthe mouse mammary gland in vivo. Total RNA was extracted from mousemammary glands at different stages of development. Northern analysesusing cDNA_probes for mouse.casein, Id-1 and Id-2 were performed. Vindicates virgin; P indicates pregnant at days 2, 5, 12 and 18 and Lindicates lactation mammary gland.

As seen in FIG. 11, β-casein mRNA was evident only during mid and latepregnancy and during lactation. When the blot was then reprobed with amouse Id-1 cDNA, Id-1 mRNA expression resulted. Such Id-1 expression wasinversely correlated with β-casein expression, suggesting a similar rolefor Id-1 gene in vivo to that observed in the SCp2 cells, that is, Id-1expression declines when the mammary gland proceeds towards fulldifferentiation as, for example, in lactation stage. On the other hand,expression of Id-2 mRNA was barely detectable in virgin gland and at thebeginning of pregnancy. Its expression increased at day 12 of pregnancy,when epithelial cells start producing the milk protein β-casein. Id-2expression was at its highest level toward the end of pregnancy (day 18)and lactation, when the epithelial cells were fully differentiated.

The above results show that the expression pattern of Id-2 mRNA or geneexpression is different from that of Id-1 mRNA. Id-2 expression level isopposite to that of Id-1 expression during periods of cell growth anddifferentiation. This further indicates a differentiating role for Id-2,in contrast to Id-1, during mammary gland development.

The terminal development of the mammary gland involves the contributionof proliferative as well as differentiative events. These events must betightly coordinated. Id-2 as well as Id-1 were shown to play a centralrole in this regulation by negatively regulating different sets of bHLHproteins. Moreover, the expression of these two genes was found to betightly coordinated.

c. Analysis of Id-2 Expression in Breast Cancer Cells

To confirm that similar findings to those found in murine mammaryepithelial cells in vitro and in vivo, Id-2 expression was investigatedin human breast cancer cell lines in culture using the same mouse Id-2cDNA probe.

For this purpose, the two T47D and MCF7 cancer cell lines which displaynon-aggressive and differentiated characteristics in culture (in absenceof estrogen), and the two highly aggressive and metastatic MDA-MB-231and MDA-MB-436 cell lines were used. The cells lines were describedabove. Results are seen in FIG. 12.

FIG. 12A is a Northern analysis of Id-1 and Id-2 mRNA expression inhuman breast cancer cell lines. Cells were cultured in serum-free mediumfor 48 hours before RNA was extracted and subjected to blotting. Lane 1shows T47D cancer cell line; lane 2 shown MCF-7 cancer cell line; lane 3shows MDA-MB-231 cancer cell line and lane 4 shows MDA-MB-436 cancercell line. FIG. 12B shows Id-1 and Id-2 expression in MCF-7 growing in10% FBS (lane 1) and MCF-7 cultured in serum-free medium for 24 hours(lane 2).

As seen if FIG. 12A, when cultured in serum-free conditions for 48 hrs,MCF-7 cells, and to a lesser extent T47D cells, expressed high levels ofId-2 mRNA. However, Id-2 expression was undetectable in the twoaggressive cell lines MDA-MB-231 and MDA-MB-436 where, as expected, Id-1was highly expressed. Id-1 expression was not detected in non-aggressiveT47D and MCF-7 cancer cells.

These results again confirm, this time in human breast cancer cells, theinverse correlation between the expression of the two HLH proteins thatwas previously determined to exist in mammary epithelial cells and implya different role for Id-2 from Id-1 in breast cancer cell phenotypes.This is seen especially clearly in FIG. 12B, where, uponserum-withdrawal, the levels of Id-2 mRNA were found to be increased inMCF-7 cells whereas the levels of Id-1 mRNA were decreased. All the datapresented above clearly show the role of the two helix-loop-helixproteins, Id-1 and Id-2, as molecular switches not only betweengrowth/invasion and differentiation in mammary epithelial cells, butalso during breast cancer progression.

8. Targeting Id-1 Reduces Breast Cancer Cell Invasion In Vitro

To determine whether the Id-1 is a key gene which regulates theaggressive phenotype of human breast cancer cells, studies wereperformed to determine whether Id-1 antisense expression converts a veryaggressive and metastatic breast cancer cell into a non-aggressive one.

For this purpose, the human Id-1 cDNA was expressed in a sense as wellas an antisense orientation in human metastatic MDA-MB436 breast cancercells using an amphotropic LXSN-Id-1 sense and antisense retrovirus.Neomycin was used to select for virus-expressing cells. Results areshown in FIG. 13.

FIG. 13 is a Western analysis of Id-1 expression of highly aggressiveand invasive MDA-MB436 cancer cells. Actin was used as control. Lane 1shows MDA-MB436 cells as control against MDA-MB436 treated with Id-1sense retrovirus (lane 2) or MDA-MB436 treated with Id-1 antisenseinfected with retrovirus (lane 3).

As seen in FIG. 13, cells infected with a control virus (empty plasmid,lane 1) expressed detectable levels of Id-1 protein in serum-freemedium. The LX SN-Id-1 sense infected population (lane 2) expressed evenhigher levels of Id-1 protein whereas the LXSN-Id-1 antisense infectedcells (lane 3) expressed very low levels of Id-1 under these conditions.

The same three populations of cells were then tested in a Boyden Chamberinvasion assay to compare their ability to migrate and invade areconstituted basement membrane. Results are seen in FIG. 14.

FIG. 14 shows results of the invasion assay where the assays wereperformed in modified Boyden Chambers assay described in Example 5 with8 μm pore filter inserts for 24-well plates obtained from CollaborativeResearch. Filters were coated with 10-12 μl of ice-cold Matrigel (7.3mg/ml protein) obtained from Collaborative Research. Cells (100,000 perwell) were added to the upper chamber in 200 μl of the appropriatemedium containing 0.1% bovine serum albumin (BSA). In general, cellswere assayed in triplicate or quadruplicate, and the results averaged.The lower chamber was filled with 300 μl of NIH-3T3 cell-conditionedmedium according to Cancer Res., 47:3239-3245 (1987). After a 20 hoursincubation, cells were fixed with 2.5% glutaraldehyde in PBS and stainedwith 0.5% toluidine blue in 2% Na₂CO₃. Cells that remained in theMatrigel or attached to the upper side of the filter were removed withcotton tips. Cells on the lower side of the filter were counted usinglight microscopy.

The invasive activity of each cell population was proportional to thelevel of Id-1 protein expression as seen in Western blot shown in FIG.13. The population with high levels of Id-1 (LXSN-Id-1 sense cells, lane2) was much more invasive than the population expressing low levels ofId-1 (LXSN-Id-1 antisense cells, lane 3). The invasive activity of thecontrol population expressing intermediate levels of Id-1 protein wasalso intermediate (lane 1).

These results further confirm that the agressivity and invasiveness ofthe human breast cancer cells can be attributed to the high expressionof Id-1 gene and also show that agressivity of cells expressing Id-1protein can be reduced or eliminated by treatment with an Id-1 antisenseconstructs. Consequently, the expression of Id-1 in human breast cancercells is a good prognostic and diagnostic tool for detection ofaggressive breast cancer and for distinguishing such aggressive andinvasive cancer from the non-invasive cancer cells attributable to theirexpressing Id-2 protein.

9. Targeting Id-1 Reduces Breast Cancer Cell Metastasis In Vivo

Following the finding that targeting Id-1 with an antisense comprisingconstruct reduces agressivity of breast cancer cells in vitro, furtherstudies were undertaken to determine if the same would be valid forbreast cancer cells in vivo, and if the metastatic propensity of cancercells expressing Id-1 could be changed to nonaggressive cells.

In order to determine the role of Id-1 in the metastatic process invivo, the 4T1 murine metastatic breast cancer cell line which express,like human MDA-MB231 and MDA-MB436 cells, high levels of Id-1 mRNA andprotein and which metastasize to the lungs were used. In order todeliver the Id-1 antisense constructs, the technique of cationicliposome-DNA complex (CLDC)-based intravenous gene delivery according toJ. Biol. Chem., 274:13338-13344 (1999) was utilized. This CLDC-basedintravenous (iv) delivery (tail vein injections) of Id-1 antisenseconstruct, such as plasmid, significantly reduced the metastatic spreadof 4T1 breast cancer cells in 4T1BalbC mice. Results are seen in FIG.15.

FIG. 15 is a graph illustrating a tumor reduction in 4T1/BalbC micetreated with various constructs. Specifically, the mice were treatedwith luciferase (lane 1), with irrelevant gene serving as anothercontrol (lane 2) and with Id-1 antisense (lane 3).

Results shown in FIG. 15 clearly show that the number of highlyaggressive and metastatic tumor decreases significantly when the tumorcells are targeted with Id-1 antisense construct.

Specifically, a single injection of CLDC containing Id-1 antisense,three days after iv injection of 50,000 4T1 cells, dramatically reducedthe total number of lung metastases (lane 3), when compared totumor-bearing mice treated with CLDC containing control genes(luciferase as well as an irrelevant gene, lanes 1 and 2).

These results show first that the aggressive tumor growth and metastasiscan be treated with antisense Id-1 construct and, second, thatCLDC-based plasmid antisense delivery, which is a novel deliveryapproach, is a practical way of achieving such delivery.

10. Cumulative Evidence for Id-1 and Id-2 Function in Breast CancerAggressivity and Diagnosis and Treatment Thereof

Invention described herein showed that aggressive metastatic breastcancer cells express high levels of Id-1 mRNA because of a loss ofserum-dependent relation that is mediated by the 2.2-kb region of thehuman Id-1 promoter. This suggests that unregulated Id-1 gene expressionmay be an important regulator of the aggressive phenotype of a subset ofhuman breast cancer cells. The results disclosed herein furtherimplicated Id-1 gene as a critical downstream target of steroid hormonesand critical mediator of the aggressive phenotype in a subset of humanbreast cancer cells.

Specific findings are as follows:

The Id-1 gene is highly expressed during proliferation, and isdown-regulated when mammary epithelial cells differentiate. The Id-2gene is not expressed in growing mammary epithelial cells, and isup-regulated during differentiation.

Id-1 expression declines when the mammary gland proceeds toward fulldifferentiation during pregnancy and at the lactation stage. Id-1 thusis expressed primarily in cells which are nondifferentiated or begin todifferentiate.

In non-invasive breast cancer cell, the expression of Id-1 gene can beinduced by culturing these cells in the presence of serum. However, inthese non-invasive breast cancer cells, this gene is not expressed andthe expression cannot be induced in serum-free medium. To the contrary,the invasive metastatic cancer cells express Id-1 gene in both the serumcontaining and serum-free medium. Consequently, the invasive metastaticbreast cancer cells do not need Id-1 expression induction by serum butit is in their cellular make-up to express Id-1 gene constitutively.

The constitutive expression of Id-1 inhibits differentiation of mammaryepithelial cells, and induces proliferation and invasion.

Certain aggressive breast cancer cells constitutively express highlevels of Id-1 protein, apparently due to the loss of serum-dependentregulation.

The expression of Id-1 directly correlates with the level ofaggressiveness in breast cancer cell lines and evaluation of the breastcells agressivity can be made in breast cancer biopsies by determining alevel of Id-1 protein expression. Almost all examined ductal carcinomasin situ (DCIS) were negative for Id-1 staining. However, the majority(51%) of infiltrating Grade 3 carcinomas of ductal origin were stronglyId-1 positive. These results confirm that Id-1 is a reliable prognosticmarker for breast cancer invasiveness and metastatic propensity.

The expression of Id-2 directly correlates with the level ofdifferentiation and non-aggressiveness breast cancer cells. Id-2 isinvolved in and its up-regulation occurs during mammary celldifferentiation. Such up-regulating can be effectively negated with Id-2antisense carrying construct.

Id-1 and Id-2 are fair indicators of breast cancer presence andagressivity and each indicates and is found in a different type ofcancer cells. Detection of Id-1 expression indicates presence of highlyaggressive, metastatic and invasive cancer cells. Detection of Id-2expression indicates presence of noninvasive cancer cells. Theexpression pattern of Id-2 protein is different from that of Id-1protein. Id-2 expression level is opposite to that of Id-1 expressionduring periods of cell growth and differentiation.

The expression of Id-1 in human breast cancer cells is a good prognosticand diagnostic tool for detection of aggressive breast cancer and fordistinguishing such aggressive and invasive cancer from the non-invasivecancer cells attributable to their expressing Id-2 protein.

The aggressive tumor growth can be treated with antisense Id-1 constructand CLDC-based plasmid antisense delivery is a practical way ofachieving such delivery.

The Id-2 protein level changes dramatically at different stages ofbreast development in the opposite direction of the Id-1 protein level.The increase in the level of Id-2 protein is crucial for normal breastdevelopment, and breast cancer cells that produce high levels of Id-2protein do not, or are less likely to, migrate and invade. They willremain localized in the breast, will not metastasize and are thereforeeasier to treat.

II. Method for Detection, Diagnosis and Prognosis of Breast Cancer

A method for detection of the aggressive and invasive cancer cells ornoninvasive cancer cells comprises detection of Id-1 and/or Id-2 genes,or their ratio, or Id-1 and/or Id-2 products, or their ratio, asdiagnostic markers for detection of metastatic agressivity of carcinoma.Such detection is useful both for diagnostic and particularly forprognostic purposes in patients.

As earlier noted, Id-1 protein is expressed at elevated levels inaggressive breast cancer cell lines. These highly aggressive breastcancer cells have lost serum-dependent regulation of the Id-1 geneexpression, which results in constitutively high levels of Id-1 protein.Indeed, it appears that the Id-1 protein plays a key role in themalignant progression of a subset of aggressive and invasive humanbreast cancers.

While Id-1 represents a marker of poor prognosis for invasive andmetastatic breast cancer, in contrast Id-2 represents a marker of goodprognosis for breast cancer since the breast cancer cells expressingId-2 will tend to be localized and not metastasized.

A patient found to have breast cancer, but breast cancer in which Id-2is being expressed, is one for whom the prospect of recovery by simplerand less invasive techniques, such as lumpectomy, is suggested. Such apatient, therefore, likely does not need the more radical treatments,such as mastectomy, radiation or chemotherapy, that would otherwise berecommended for invasive breast cancer when the high expression of Id-1protein is detected.

A. Methods Suitable For Detection of Id-1/Id-2 Expression Products

In a therapeutic method of this invention described below, the treatingphysician who has, for example, found tumors/lumps will typically send abreast tissue sample, as a biopsy, to a pathologist for examination anddiagnosis.

The examination and classification of the tissue is typically based on avisual inspection of tissue morphology. For example, the pathologist candecide whether the biopsied tissue is an infiltrating or invasivecarcinoma or whether it is ductal carcinoma in situ (DCIS). Within eachof these classifications the pathologist attempts to assign grades ofaggressiveness, such as infiltrating Grade 1 carcinoma, which is notoverly aggressive, or infiltrating Grade 3 carcinoma that is veryaggressive.

The development of a DCIS into a highly aggressive and metastatic breasttumor involves a series of sequential steps; breast epithelial cellsmust lose the ability to interact with other cells, acquire the abilityto digest the surrounding basement membrane, migrate toward the bloodstream, and survive and proliferate in ectopic sites. Invasiveness marksthe onset of metastasis, which is a hallmark of often final malignantprogression.

For detection of Id-1/Id-2 proteins, the immunohistochemistry analysisusing Id-1 antibodies can be used together with Id-2 antibodies, since adetermination of both Id-2 and Id-1 expression, or lack of expressionfor one with respect to the other, will help the treating physician andpathologist determine the type or grade of breast cancer. Thus,determination of Id-1 or Id-2 expression ratio, or the ratio of Id-1 toId-2 gene product such as proteins or mRNA, can be performed by variousdetection methods known to the art such as immunohistochemistry or insitu hybridization.

Where the gene products to be determined are proteins, then the Id-1 andId-2 proteins can be detected and analyzed, for example, byimmunohistochemistry as described in Examples 8 and 10, where anti-serumis directed against the gene product of interest.

Additionally, the presence or absence of a gene product, mRNA, can bedetected in accordance with this invention through the use of probes,primers or anti-sense molecules. Such detection utilizes, for example,probes for detecting and/or analyzing Id-1 and Id-2 expression, such asin situ hybridization to detect target mRNA.

Where the Id-1 and Id-2 gene products to be detected are, for example,mRNA, then the detection can be accomplished, for example, with nucleicacid probes. Other means for detecting the presence or absence of themRNA gene product that are known and useful can utilize primers andanti-sense molecules.

The DNA of the invention encoding the Id-1 or Id-2 gene or homologues,analogues, or fragments thereof may be used in accordance with theinvention to diagnose disease states which are phenotypic of an aberrantId-1 or Id-2 genotype or of aberrant Id-1 or Id-2 expression.

By way of another example, but not by way of limitation, many tumors maybe characterized by a lack of, or excess of, Id-1 or Id-2 activity whichmay stem from mutations in the Id-1 or Id-2 coding or regulatorysequence.

In both of the examples above, afflicted cells, tissue sections orbiopsy specimens may be screened with the Id-1 or Id-2 DNA sequences ofthe invention and isolated Id-1 or Id-2 sequenced to determine whichmutations in Id-1 or Id-2 are associated with the diseases. The DNAs ofthe invention may also be used to determine whether an individualcarries an aberrant Id-1 or Id-2 gene.

The detection of the aberrant Id-1 or Id-2 DNA is conducted by PCRamplification, from a small tissue sample. Detection of Id-1 or Id-2product may also be via in situ hybridization or immunocytochemistry ofpathology or biopsy specimens.

The best mode contemplated for practicing the invention for detection ofbreast cancer cell agressivity is to perform assays from biopsied breasttissue for both Id-1 and Id-2 proteins or mRNAs. In practice, one ormore of the sections made from an embedded biopsy are tested for Id-1and for Id-2. The results are then compared for ratios of Id-1 and Id-2,since it appears that Id-1 and Id-2 are inversely correlated. Theimportance of determining the ratios of Id-1 and Id-2 will be specificfor breast tissue and breast cancers, by contrast to other tissues andother cancers, where different ratios may be found.

B. Antibodies

In addition, Id-1 and Id-2 antibodies can be used in a number of otherdetection methods, since many of the detection methods known in the artthat will be useful in detecting Id-1 and Id-2 gene products utilizeantibodies.

One aspect of this invention is a method for using Id-1 and Id-2antibodies where the antibodies will bind to Id-1 and Id-2 proteins,respectively, if present, in a breast, cervical, ovarian, endometrium,squamous cells, prostate or melanoma tissue sample. The presence ofbound antibodies can be determined by simple visual examination, or canbe detected by other known methods, such as radioactivity orfluorescence.

For the production of antibodies, various host animals may be immunizedby injection with the Id-2 or Id-1 gene product, or a portion thereofincluding but not limited to, portions of the Id-1 or Id-2 gene productin a recombinant protein. Such host animals may include but are notlimited to rabbits, mice, and rats, to name but a few.

Various adjuvants may be used to increase the immunological response,depending on the host species, including but not limited to Freund's(complete and incomplete), mineral gels such as aluminum hydroxide,surface active substances such as lysolecithin, pluronic polyols,polyanions, peptides, oil emulsions, keyhole limpet hemocyanin,dinitrophenol, and potentially useful human adjuvants such as BCG(bacille Calmette-Guerin) and Corynebacterium parvum.

Id-1 and Id-2 antibodies are commercially available. The commerciallyavailable antibodies are typically polyclonal, and bind to both themouse and human proteins.

Monoclonal antibodies may be prepared by using any technique whichprovides for the production of antibody molecules by continuous celllines in culture. These include but are not limited to the hybridomatechnique originally described in Nature, 256:495-497 (1975), the humanB-cell hybridoma technique, Immunology Today, 4:72 (1983), Proc. Natl.Acad. Sci., 80:2026-2030 (1983) and the EBV-hybridoma technique,Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96(1985).

In addition, techniques developed for the production of “chimericantibodies”, Proc. Natl. Acad. Sci., 81:6851-6855 (1984), Nature,312:604-608 (1984), Nature, 314:452-454 (1985) by splicing the genesfrom a mouse antibody molecule of appropriate antigen specificitytogether with genes from a human antibody molecule of appropriatebiological activity can be used. Alternatively, techniques described,for example, the production of single chain antibodies (U.S. Pat. No.4,946,778) can be adapted to produce single chain antibodies specific toone of the binding partners.

Antibody fragments which recognize specific epitopes may be generated byknow techniques. For example, such fragments include but are not limitedto: the F(ab¹)₂ fragments which can be produced by pepsin digestion ofthe antibody molecule and the Fab fragments which can be generated byreducing the disulfide bridges of the F(ab¹)₂ fragments. Alternatively,Fab expression libraries may be constructed according to Science,246:1275-1281 (1989) to allow rapid and easy identification ofmonoclonal Fab fragments with the desired specificity.

C. Id-1 and Id-2 Genes, Id-1 and Id-2 Protein—Markers for Detection ofand Targets for Treatment

Because of their negative correlation and different function in thebreast tissue, Id-1 or Id-2 genes, Id-1 or Id-1 mRNAs, or Id-1 or Id-2proteins may each individually be used as a marker for detection and/orprognosis of malignant agressivity or as a target for gene therapy.

D. Combination of Id-1 and Id-2 Genes—Marker and Target

Similarly, a ratio of both genes and/expressed proteins may beadvantageously used for diagnosis and/or prognosis of breast cancercells agressivity.

E. Prognosis of Breast Cancer

In one aspect of the present invention, a method is provided that isuseful in the prognosis of breast cancer.

The method for prognosis comprises detecting expression for an Id geneproduct in breast tissue obtained from a patient, and more preferably byseeking to detect gene products, that is Id-1 and Id-2 proteins ormRNAs. For example, the presence of Id-2 gene product (protein or mRNA)and the absence of Id-1 gene product, or a relatively larger amount ofId-2 with respect to Id-1, is a prognostic indicator that breast cancercells in the breast tissue will remain localized.

III. A Diagnostic Kit for Detection of Breast and Other Types of CancerAggressivity

The invention further concerns the detection of Id-1, Id-2 or theirratio with a kit comprising anti Id-1 and/or Id-2 antibodies or Id-1and/or Id-2 probes.

The kit for detection of breast cancer agressivity is based on a methodof using Id-1 and Id-2 antibodies or probes.

The kit typically comprises a detection means for detecting either theId-1 and/or Id-2 expression product mRNA, or Id-1 and/or Id-2 product.For detection of Id-1 or Id-2 protein, antibodies for Id-1 protein arecontacted with breast tissue under conditions allowing the Id-1antibodies to bind to Id-1 protein, if present. Another sample of thesame breast tissue is similarly contacted with antibodies for Id-2protein under conditions allowing the Id-2 antibodies to bind to Id-2protein, if present. The presence of bound Id-2 antibodies with theabsence of bound Id-1 antibodies is a prognostic indicator that breastcancer cells in the breast tissue are noninvasive and remain localized.The presence of Id-1 antibodies with the absence of Id-2 binding is aprognostic indicator of the presence of aggressive cancer. Quantitatingboth responses derives a ratio of Id-1/Id-2. The ratio above 1 indicatesaggressive cancer. The ratio lower than 1 indicates less aggressive ornon-aggressive cancer.

IV. Method for Treatment of Breast Cancer

A method for treatment of breast, endometrial, cervical, ovarian,squamous cells or prostate carcinoma or melanoma comprises targeting ofId-1, or Id-2 genes, or a combination thereof, through delivery ofantisense transcripts, ribozymes, cationic liposomes, smalltherapeutically active molecules, drugs, peptides or organic compoundsthat disrupt Id-1 interaction with a bHLH transcription factor orenhance Id-2 gene interaction with a bHLH transcription factor and viceversa, RNA, anti-Id-1 RNAi causing degradation of homologous Id-1 mRNAs,Id-2 as a gene or a protein, ITF-2 as a gene or protein, or targetingId-1 or Id-2 proteins with antibodies or with compounds which eitherenhance or inhibit their production.

A. Gene Therapy for Treatment

Gene therapy provides a way to manipulate genetic make-up of the cell.There are two general approaches to gene therapy.

The first approach utilizes the introduction into a patient of a vectorthat inserts into the genetic code a sequence in the case of breastcancer, Id-2 sequence, that replaces the more aggressive Id-1 gene, withthe less aggressive Id-2 gene.

The second approach utilizes the genetic code of Id-1 or Id-2 to deliverto the breast cells Id-1 or Id-2 antisense molecules that enter thebreast cells and by sequence recognition, selectively inhibit the gene,Id-1 gene in this case, expression.

Both approaches are intended to be within the scope of this invention.

B. Gene Therapy Approaches

A variety of gene therapy approaches may be used in accordance with theinvention to modulate expression of the Id-1 or Id-2 gene in vivo. Forexample, antisense DNA molecules may be engineered and used to blocktranslation of mRNA in vivo.

Alternatively, ribozyme molecules may be designed to cleave and destroythe Id-1 or Id-2 mRNAs in vivo.

In another alternative, oligonucleotides designed to hybridize to the 5′region of the Id-1 or Id-2 gene (including the region upstream of thecoding sequence) and form triple helix structures may be used to blockor reduce transcription of the Id-1 or Id-2 gene.

In yet another alternative, nucleic acid encoding the full lengthwild-type Id-1 or Id-2 message may be introduced in vivo into cellswhich otherwise would be unable to produce the wild-type Id-1 or Id-2gene product in sufficient quantities or at all.

In a preferred embodiment, the antisense, ribozyme and triple helixnucleotides are designed to inhibit the translation or transcription ofId-1 with minimal effects on the expression of Id-2. In a preferredembodiment, the antisense, ribozyme and triple helix nucleotides aredesigned to inhibit the translation or transcription of Id-2 withminimal effects on the expression of Id-1. To accomplish this, theoligonucleotides used are designed on the basis of relevant sequencesunique to Id-1 or Id-2, i.e., those sequences found in Id-1 but not inId-2 or Id-2 and not Id-1.

For example, and not by way of limitation, the oligonucleotides shouldnot fall within those regions where the nucleotide sequence of both Idgenes is most homologous.

Moreover, the aggressive propensity of Id-1 gene in breast cancer cellsmay be effectively targeted with Id-1-antisense construct and theaggressive breast cancer cells may be converted to non-aggressivenon-invasive cancer cells.

B. Targeting Delivery Vehicles and Products

The current gene delivery methods can be divided to two classes: viraland non-viral.

a. Viral Vectors

The viral vectors currently used both for target validation and genetherapy are mainly of the following types:

1. Adenoviral vectors, mostly Ad2 and Ad5-based recombinant vectorswhich may or may not contain targeting elements, either via geneticmodification or chemical modification of the viral capsid. It can eitherbe a replication-defective virus or a selectively replicating competentvirus.

2. Lentivirus vectors with the same modifications as stated foradenoviral vectors.

3. Adeno-associated viral vectors (AAV).

4. Retroviral vectors.

Among these four, the first two are most commonly used for cancerindications.

b. Non-viral Gene Delivery Vehicles

There are several non-viral based gene delivery systems.

1. One class includes physical devices to facilitate uptake includingdirect injection of plasmid DNA, gene guns, electroporation,microinjection, electrical pulses, and ultrasound.

2. The other class of non-viral based methods more relevant to systemicdelivery are the synthetic gene delivery systems that are defined bytheir use of:

-   -   i) cationic lipids, also called cationic liposomes or        lipoplexes; Cationic lipids enter the cell by endocytosis and        traverse the cytoplasm through various endocytic compartments.        In this process, these complexes are either targeted to        lysosomes for degradation, or are released into the cytoplasm.        One way to deliver gene to its target is by forming cationic        liposome-DNA complex which targets gene expression to vascular        endothelial cells, macrophages and tumor cells.

In practice, for example, cationic liposome-Id-2-DNA complex is preparedand targeted to carcinoma cells to replace a highly aggressive Id-1 genewith less aggressive Id-2 gene.

-   -   ii) polycationic polymers or polyplexes.

3. Another delivery vehicle for targeting of the Id-1 gene is RNAinterference (RNAi) process. The RNAi process utilizes asequence-specific post-transcriptional gene silencing of Id-1 gene byproviding a double-stranded RNA (Id-1-dsRNA) that is homologous insequence to the Id-1 gene. Small interfering RNAs (siRNAs) generated byribonuclease III cleavage from longer Id-1-dsRNA are the mediators ofsequence-specific Id-1-mRNA degradation.

4. Another type of targeting delivery vehicles are recently newlydeveloped nanotechnologies. There are currently two nanotechnologiesdeveloped and available for gene transfers and drug delivery, namelydendritic polymers and micellar nanoparticles. Dendritic polymers, alsocalled dendrimers are polymers suitable and useful for the design andassembly of nanoscale materials. Micellar nanoparticles are uniquesynthetic lipid vesicles that fuse with cell membrane.

Non-viral based gene delivery systems offer ease of preparation,enhanced DNA packaging capacity and low immunogenicity.

In terms of the type of molecules the gene delivery vehicles candeliver, they include plasmids expressing cDNA of the therapeutic genes(ITF-2 or Id-2, for example in the breast) or the actual therapeuticmolecules. Additionally, anti-sense expressing plasmids (Id-1 antisense,for example) or the anti-sense oligonucleotides themselves may be usedas a delivery vehicle to target cancer genes. Small molecule inhibitorsof Id-1-interacting proteins are also suitable.

The use of antisense DNA and DNA vectors is described, for example, inClinical Trials of Genetic Therapy with Antisense DNA and DNA Vectors,Ed. Eric Wickstrom, Marcel Decker, Inc. (1998), incorporated byreference.

In conclusion, there are different ways to develop cancer therapeuticsusing helix-loop-helix proteins as targets. These different waysinclude, but are not limited to, the ones previously described.

VI. Pharmaceutical Formulations and Compositions

Any of the identified compounds, antisense DNA molecules, antibodies,delivery vehicles, etc., can be administered to a mammal, including ahuman patient, directly, or in pharmaceutical compositions comprisingits admixture with suitable carriers or excipient(s) at dosestherapeutically effective to treat or ameliorate a breast, cervical,ovarian, endometrium, squamous cells and prostate cancer and melanoma.

A therapeutically effective dose refers to that amount of thecomposition sufficient to result in treatment or amelioration ofsymptoms associated with aggressive cancer cells. Various techniques forformulation and administration of the compositions of the instantapplication may be found in “Remington's Pharmaceutical Sciences,” MackPublishing Co., Easton, Pa., latest edition.

The products of the invention may be designed or administered for tissuespecificity. If the compound comprises a nucleic acid molecule,including those comprising an expression vector, it may be linked to aregulatory sequence which is specific for the target tissue, such as thebreast tissue, cervix, ovarian, endometrium, squamous cells, prostate orskin, etc., by methods which are know in the art including those setforth in Ann. Oncol., 5 Suppl 4:59-65 (1994); Gene, 145:305-310 (1994);Surgery, 116:205213 ((1994); Cancer Res., 54:4266-4269; Cancer, 74(Suppl. 3):1021-1025 (1994); Proc. Nat'l. Acad. Sci. USA, 91:1460-1464;Exp. Hematol., 22:223-230; Prog. Clin. Biol. Res., 388:361-365 (1994).The compounds of the invention may be targeted to specific sites bydirect injection to those sites, such as breast, in the case of breastcancer.

Pharmaceutical compositions suitable for use in the present inventioninclude compositions wherein the active ingredients are contained in aneffective amount to achieve its intended purpose. More specifically, atherapeutically effective amount means an amount effective to stopaggressive metastatic cancer growth and to alleviate the existingsymptoms of the subject being treated. Determination of the effectiveamounts is well within the capability of those skilled in the art,especially in light of the detailed disclosure provided herein.

For any compound used in the method of the invention, thetherapeutically effective dose can be estimated initially from cellculture assays. For example, a dose can be formulated in animal modelsto achieve a circulating concentration range that includes the IC50 (thedose where 50% of the cells show the desired effects) as determined incell culture. Such information can be used to more accurately determineuseful doses in humans.

A therapeutically effective dose refers to that amount of the compoundthat results in amelioration of symptoms or a prolongation of survivalin a patient. Toxicity and therapeutic efficacy of such compounds can bedetermined by standard pharmaceutical procedures in cell cultures orexperimental animals, e.g., for determining the LD50 (the dose lethal to50% of the population) and the ED50 (the dose therapeutically effectivein 50% of the population).

The dose ratio between toxic and therapeutic effects is the therapeuticindex and it can be expressed as the ratio between LD50 and ED50.Compounds which exhibit high therapeutic indices are preferred. The dataobtained from the cell culture assays described above and animal studiescan be used in formulating a range of dosage for use in humans. Thedosage of such compounds lies preferably within a range of circulatingconcentrations that include the ED50 with little or no toxicity.

The dosage may vary within this range depending upon the dosage formemployed and the route of administration utilized. The exactformulation, route of administration and dosage can be chosen by theindividual physician in view of the patent's condition. Dosage amountand interval may be adjusted individually to provide plasma levels ofthe active moiety which are sufficient to maintain the desired effects.

In cases of local administration or selective uptake, the effectivelocal concentration of the drug may not be related to plasmaconcentration.

The amount of composition administered will, of course, be dependent onthe subject being treated, on the subject's weight, the severity of theaffliction, the manner of administration and the judgment of theprescribing physician.

The pharmaceutical compositions of the present invention may bemanufactured in a manner that is itself known, e.g., by means ofconventional mixing, dissolving, granulating, dragee-making, levigating,emulsifying, encapsulating, entrapping or lyophilizing processes.

Pharmaceutical compositions for use in accordance with the presentinvention thus may be formulated in conventional manner using one ormore physiologically acceptable carriers comprising excipients andauxiliaries which facilitate processing of the active compounds intopreparations which can be used pharmaceutically. Proper formulation isdependent upon the route of administration chosen.

For injection, the agents of the invention may be formulated in aqueoussolutions, preferably in physiologically compatible buffers such asHank's solution, Ringer's solution, or physiological saline buffer. Fortransmucosal administration, penetrants appropriate to the barrier to bepermeated are used in the formulation. Such penetrants are generallyknown in the art.

For oral administration, the compounds can be formulated readily bycombining the active compounds with pharmaceutically acceptable carrierswell known in the art. Such carriers enable the compounds of theinvention to be formulated as tablets, pills, dragees, capsules,liquids, gels, syrups, slurries, suspensions and the like, for oralingestion by a patient to be treated. Pharmaceutical preparations fororal use can be obtained solid excipient, optionally grinding aresulting mixture, and processing the mixture of granules after addingsuitable auxiliaries, if desired, to obtain tablets or dragee cores.Suitable excipients are, in particular, fillers such as sugars,including lactose, sucrose, mannitol, or sorbitol; cellulosepreparations such as, for example, maize starch, wheat starch, ricestarch, potato starch, gelatin, gum tragacanth, methyl cellulose,hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/orpolyvinylpyrrolidone (PVP). If desired, disintegrating agents may beadded, such as the cross-linked polyvinyl pyrrolidone, agar, or alginicacid or a salt thereof such as sodium alginate.

Dragee cores are provided with suitable coatings. For this purpose,concentrated sugar solutions may be used, which may optionally containgum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethyleneglycol, and/or titanium dioxide, lacquer solutions and a suitableorganic solvent or solvent mixture. Dye stuffs or pigments may be addedto the tablets or dragee coatings for identification or to characterizedifferent combinations of active compound doses.

Pharmaceutical preparations which can be used orally include push-fitcapsules made of gelatin, as well as soft, sealed capsules made ofgelatin and a plasticiser, such as glycerol or sorbitol. The push-fitcapsules can contain the active ingredients in admixture with fillersuch as lactose, binders such as starches, and/or lubricants such astalc or magnesium stearate and, optionally, stabilizers. In softcapsules, the active compounds may be dissolved or suspended in suitableliquids, such as fatty oils, liquid paraffin, or liquid polyethleneglycols. In addition, stabilizers may be added. All formulations fororal administration should be in dosages suitable for suchadministration.

For buccal administration, the compositions may take the form of tabletsor lozenges formulated in conventional manner.

For administration by inhalation, the compounds for use according to thepresent invention are conveniently delivered in the form of an aerosolspray presentation from pressurized packs or a nebulizer, with the useof a suitable propellant, e.g., dichlorodifluoromethane,trichlorofluoromethane, dichlorotetrafluorethane, carbon dioxide orother suitable gas. In the case of a pressurized aerosol the dosage unitmay be determined by providing a valve to deliver a metered amount.Capsules and cartridges of e.g. gelatin for use in an inhaler orinsufflator may be formulated containing a powder mix of the compoundand a suitable powder base such as lactose or starch.

The compounds may be formulated for parenteral administration byinjection, e.g., by bolus injection or continuous infusion. Formulationsfor injection may be presented in unit dosage form, e.g., in ampoules orin multidose containers, with the added preservative. The compositionsmay take such forms as suspensions, solutions or emulsions in oily oraqueous vehicles, and may contain formulatory agents such as suspending,stabilizing and/or dispersing agents.

Pharmaceutical formulations for parenteral administration includeaqueous solutions of the active compounds in water-soluble form.Additionally, suspensions to the active compounds may be prepared asappropriate oily injection suspensions. Suitable lipophilic solvents orvehicles include fatty oils such as a sesame oil, or synthetic fattyacid esters, such as ethyl oleate or triglycerides, liposomes orcationic liposomes. Aqueous injection suspensions may contain substanceswhich increase the viscosity of the suspension, such as sodiumcarboxymethyl cellulose, sorbitol, or destran. Optionally, thesuspension may also contain suitable stabilizers or agents whichincrease the solubility of the compounds to allow for the preparation ofhighly concentrated solutions.

Alternatively, the active ingredient may be in powder form forconstitution with a suitable vehicle, e.g., sterile pyrogen-free water,before use.

The compounds may also be formulated in rectal compositions such assuppositories or retention enemas, e.g., containing conventionalsuppository bases such as cocoa butter or other glycerides.

In addition to the formulation described previously, the compounds mayalso be formulated as a depot preparation. Such long acting formulationsmay be administered by implantation (for example subcutaneously orintramuscularly) or by intramuscular injection. Thus, for example, thecompounds may be formulated with suitable polymeric or hydrophobicmaterials (for example, as an emulsion in an acceptable oil) or ionexchange resins, or as sparingly soluble derivatives, for example, as asparingly soluble salt.

A pharmaceutical carrier for the hydrophobic compounds of the inventionis a cosolvent system comprising benzyl alcohol, a nonpolar surfactant,a water-miscible organic polymer, and an aqueous phase. Naturally, theproportions of a co-solvent system may be varied considerably withoutdestroying its solubility and toxicity characteristics. Furthermore, theidentify of the co-solvent components may be varied.

Alternatively, other delivery systems for hydrophobic pharmaceuticalcompounds may be employed. Liposomes, particularly cationic liposomes,and emulsions are well known examples of delivery vehicles or carriersfor hydrophobic drugs. Certain organic solvents such asdimethylsulfoxide also may be employed although usually at the cost ofgreater toxicity. Additionally, the compounds may be delivered using asustained-release system, such as semipermeable matrices of solidhydrophobic polymers containing the therapeutic agent. Varioussustained-release materials have been established and are well known bythose skilled in the art. Sustained-release capsules may, depending ontheir chemical nature, release the compounds for a few weeks up to over100 days. Depending on the chemical nature and the biological stabilityof the therapeutic reagent, additional strategies for proteinstabilization may be employed.

The pharmaceutical compositions also may comprise suitable solid or gelphase carriers or excipients. Examples of such carriers or excipientsinclude but are not limited to, calcium carbonate, calcium phosphate,various sugars, starches, cellulose derivatives, gelatin, and polymerssuch as polyethylene glycols.

Many of the compounds of the invention may be provided as salts withpharmaceutically compatible counterions. Pharmaceutically compatiblesalts may be formed with many acids, including but not limited to,hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc.

Salts tend to be more soluble in aqueous or other protonic solvents thatare the corresponding free base forms.

Routes of Administration

Suitable routes of administration may, for example, include oral,rectal, transmucosal, transdermal, or intestinal administration,parenteral delivery, including intramuscular, subcutaneous, intravenous,intraperitoneal or intranasal.

Alternatively, one may administer the compound in a local rather thansystemic manner, for example, via injection of the compound directlyinto an affected area, often in a depot or sustained releaseformulation.

Furthermore, one may administer the drug in a targeted drug deliverysystem, for example, in a liposome coated with an antibody specific foraffected cells. The liposomes will be targeted to and taken upselectively by the cells.

It is to be understood that while the invention has been described abovein conjunction with preferred specific embodiments, the description andexamples are intended to illustrate and not limit the scope of theinvention.

Example 1

Production of pBabe-Id-1 Retroviral Vector and Virus

This example describes production of pBabe-Id-1 retroviral vector andvirus.

The full-length human Id-1 cDNA was excised from CMV-Id-1 and clonedinto pBabe-puro, a gift from Dr. Hartmut Land, ICRF, London, UnitedKingdom. Clones in which the Id-1 cDNA was inserted in the senseorientation (pBabe-Id-1) were selected for use.

pBabe-Id-1 was transfected into the TSA54 packaging cell line (CellGenesis; Foster City, Calif.) using calcium phosphate. Twenty-four hoursafter transfection, culture medium containing infectious virus washarvested twice at 4 hour intervals and was frozen at −80 C. Viraltiters were determined by reverse-transcriptase activity. Briefly,thawed aliquots of harvested media were incubated with poly(A) (20ng/μl), oligo dT (10 ng/μl), and [³H]TTP (0.1 μCi/μl) in reaction buffer(50 mM Tris-HCl, 75 mM Kcl, 0.5 mM EGTA, and 5 mM MgCl₂) for 30 minutesat 37° C. The reaction mixture was spotted on Whatman DE81 paper, whichwas washed with 2×SSC and counted in a scintillation counter. One unitof MMLV reverse transcriptase (Life Technologies, Inc.) was subjected tothe same reaction, and the amount of incorporated [³H]TTP was defined as1 RT unit. The retroviral titer (RT units/ml) was determined bycomparing the amount of [³]TTP incorporated by the virus-containingmedium with that incorporated by MMLV reverse transcriptase.

Example 2 Cell Culture and Retroviral Infection

This example describes cell lines, cell culture conditions andretroviral infection.

Human breast cancer cell lines MCF7, T47D, and MDA-MB-231 were purchasedfrom the American Tissue Culture Collection (ATCC). MetastaticMDA-MB-435 cells from ATCC were selected for a highly aggressivephenotype by passage in immunodeficient mice. Briefly, cells wereinjected into nude mice and fast growing tumors were harvested 3-4 weekslater and processed for in vitro cultivation. Fibroblasts wereeliminated from the culture by differential trypsinization, and thetumor cells were expanded and cryopreserved for future use.

Breast cancer cell lines were grown in DMEM or RPMI 1640 obtained fromUniversity of California, San Francisco, containing 10% fetal bovineserum and insulin (5 μg/ml, Sigma). For experiments using serum-freemedium, fetal bovine serum was omitted.

Approximately eight RT-units of either pBabe-puro or pBabe-Id-1retrovirus were mixed with 5 ml of medium containing 4 μg/ml polybreneand were added to T47D cells in 100-mm dishes. Cells expressing theretroviral genes were selected in 0.6 μg/ml puromycin, which killed allof the mock-infected cells within three days, whereas 80 or 30% of thepBabe-puro- or pBabe-Id-1-infected cells, respectively, survived. Thesepuromycin-resistant cells are referred to as T47D-pBO or T47D-Id-1. Toestablish single-cell clones, the T47D-Id-1 population was plated at 1-2cells/well in 24-well tissue culture plates. Clones that grew in thewells were expanded.

Example 3 RNA Isolation and Northern Analysis

This example describes conditions used for RNA isolation and Northernanalysis.

Total cellular RNA was isolated and purified as described in Anal.Biochem., 162:156-159 (1987). Twenty μg were separated byelectrophoresis through formaldehyde-agarose gels and transferred to anylon membrane (Hybond N; Amersham). The membrane was hybridized to a³²P-labeled human Id-1 cDNA or Id-2 or. casein probe according to J.Biol. Chem., 269:2139-2145 (1994) and was washed and exposed to XAR-5film for autoradiography. The same blot was hybridized to a 28S rRNAprobe to control for RNA integrity and quantitation.

Example 4 Western Analysis

This example describes conditions used for Western analysis of breastcancer cells.

Cells were lysed in 2×Laemmli buffer and stored at

−70° C. Protein concentration was determined by the DC protein assay(Bio-Rad, Hercules, Calif.). Samples (20-30 μg) were separated bySDS-PAGE and were transferred to a Immobilin-P filter (Millipore) bystandard methods. The membrane was blocked for 1 hour at roomtemperature with TBST (20 mM Tris Base, 137 mM NaCl, 3.8 mM, HCl, and0.1% Tween 20) containing 5% nonfat milk, and incubated with a rabbitpolyclonal antibody against human Id-1 or Id-2 (C-20; Santa CruzBiotechnology) or with a rabbit polyclonal antibody specific for thePR-A and PR-B forms of the Pg receptor (C-20; Santa Cruz Biotechnology)for 1.5 hours. The membrane was washed, incubated with secondaryantibody (goat antirabbit IgG-horseradish peroxidase; Santa CruzBiotechnology), washed again, and developed for enhancedchemiluminescence using the Amersham ECL kit, according to thesupplier's instructions.

Example 5 Boyden Chamber Invasion Assays

This example illustrates conditions used for Boyden Chamber invasionassays.

Invasion assays were performed in modified Boyden chambers with 8 μmpore filter inserts for 24-well plates (Collaborative Research). Filterswere coated with 10-12 μA of ice-cold Matrigel (8 mg/ml protein;Collaborative Research). Cells (80,000 per well) were added to the upperchamber in 200 μA of the appropriate medium containing 0.1% BSA. Cellswere assayed in triplicate or quadruplicate, and the results wereaveraged. The lower chamber was filled with 300 μl of NIH-3T3cell-conditioned medium. After a 20 hour incubation, cells were fixedwith 2.5% glutaraldehyde in PBS and were stained with 0.5% toluidineblue in 2% Na₂CO₃. Cells that remained in the Matrigel or attached tothe upper side of the filter were removed with cotton tips. Cells on thelower side of the filter were counted using light microscopy.

Example 6 [³H]-Thymidine-Labeling

This example describes conditions used for labeling cells with[³H]-thymidine.

Cells cultured on coverslips were given [³H]-thymidine (10 μCi/ml; 60-80Ci/mmol; Amersham) for the last 16 hours of the experiments, unlessotherwise indicated, whereupon they were fixed with methanol/acetone(1:1) and stained with DAPI. [³H]-thymidine-labeling was developed asdescribed previously in Mol. Cell. Biol., 18:4577-4588 (1988). Thepercentage of labeled nuclei was calculated by comparing the number of[³H]-thymidine-labeled nuclei with the number of DAPI-stained nuclei ina given field, using phase contrast and fluorescence microscopy.

Example 7 Antisense Oligonucleotide Treatment

This example describes conditions used for antisense oligonucleotidetreatment of T47D cells.

Phosphorothiolated oligonucleotides were made by Life Technologies, Inc.The Id-1 antisense oligonucleotide and nonspecific controloligonucleotide were described in J. Biol. Cheml, 269:2139-2145 (1994).T47D cells were cultured on coverslips in serum-free medium for 2 days.On days 3 and 4, the medium was changed in the morning to serum-freemedium containing either E2 (10 nM), or E2 and the oligonucleotides (10μM). On the evening of day 4, protein was extracted from one set ofdishes, whereas [³H]-thymidine was added to the other set for anadditional 16 hours. Cells were fixed on day 5 and assessed for labelednuclei as described above.

Example 8 Immunohistochemistry

This example describes conditions used for immunohistochemical treatmentof tumor tissue sections.

Formalin-fixed paraffin-embedded tumor tissue sections obtained from theCPMC patient protein expression in both DCIS and infiltrating Grades 1,2 and 3 ductal carcinomas. Slides were de-waxed, re-hydrated, and placedin a container containing 1 liter of 0.01 M citrate buffer (pH 6.0);they were then microwaved at 700 W for 20 minutes, allowed to remain inthe hot citrate buffer for 15 minutes, and cooled down in running coldwater. The slides were washed in deionized water and incubated in 10%nonfat dry milk for 30 minutes at room temperature, washed in TBS, andincubated with 1 μg/ml of anti Id-1 antibody overnight at 4° C. Controlslides were incubated with rabbit immunoglobulins. The slides werewashed in TBS and incubated with biotinylated swine antirabbit F(ab′)₂fragments (I:400) for 30 minutes. After washing in TBS, endogenousperoxidase was visualized by incubating in 0.5 mg/mldiaminobenzidine-4-HCl and 0.03% hydrogen peroxide in TBS for threeminutes. The slides were washed in TBS and water before mounting.

Example 9 Manipulation of Id-2 Expression in Breast Cells

This example describes methods used for manipulation of Id-2 expressionin breast cells.

Id-2 cDNA was digested with XbaI and HindIII to isolate a 1.2 kbfragment. The viral LXSN vector that was used for the mouse Id-2 cDNAhas already been digested with EcoRI, blunted with T4 DNA polymerase anddephosphorylated with CIAP. The Id-2 fragment was similarly blunted withT4 DNA polymerase, was inserted inside the dephosphorylated vector, andthe ligation product transformed into Top-10 cells. To identify theclones with sense or anti-sense orientation, digestion of the recoveredplasmids was performed with either NcoI or BstEII enzymes, and the sizeof the expected fragments determined on ethidium bromide agarose gels.The viral vectors was then packaged in TSA-54 cells (Cell Genesis;Foster City, Calif.). Mammary epithelial cells were infected withcontrol, Id-2 sense or Id-2 antisense vectors and selected withneomycin. One to two weeks after infection, resistant colonies werepooled and expanded.

Example 10 Id-2 Protein Expression in Tumor Biopsies

This example describes studies performed to demonstrate Id-proteinexpression in tumor biopsies.

Breast samples have been obtained from patients undergoingtumorectomies. In order to maintain the integrity of the tissue,paraffin embedded sections were used instead of frozen sections. Tissueswere fixed overnight at 4° C. in PBS, pH 7.2, containing 4%paraformaldehyde, dehydrated by graded alcohol and finally embedded inparaffin.

Id-2 expression is studied in a representative number of in situ andinvasive breast tumors. As for Id-1, a sample size of 30 ductalcarcinomas in situ as well as 30 invasive Grade 1 and 30 invasive Grade3 tumor tissues are used.

A specific rabbit anti-Id-2 antibody obtained from Santa CruzBiotechnology (C-20) is used for immunohistochemistry experiments.Slides are dewaxed, rehydrated and placed in a container containingcitrate buffer (pH 6.0), microwaved, allowed to remain in the hotcitrate buffer for 15 min, and cooled down in running cold water. Theslides are washed in deionized water and incubated in 10% non fat drymilk, washed in TBS and incubated with 1 μg/ml of anti Id-2 antibodyovernight at 4° C. Control slides are incubated with rabbitimmunoglobulin, washed in TBS and incubated with biotinylated swineanti-rabbit F(ab)′2 (1:400). The slides are then washed in TBS andincubated with 1:500 streptavidin-horse radish peroxidase. Peroxidase isvisualized by incubating in 0.5 mg/ml diaminobenzidine-4HCl and 0.03%hydrogen peroxide.

1. A method for treatment and amelioration of a cancer in breast,cervical, ovarian, endometrial, squamous cells, or prostate tissue ormelanoma in a patient comprising the steps of: a) providing a deliveryvehicle comprising a product which modulates Id-1 gene expression; b)delivering said delivery vehicle to said patient; and c) modulating Id-1gene expression in said patient for treatment and amelioration of acancer.
 2. The method of claim 1 wherein said cancer is breast cancer.3. The method of claim 1 wherein the product is an antisense transcript,ribozyme, or a molecule that modulates Id-1 expression, or RNAi.
 4. Themethod of claim 3 wherein the product is a molecule that modulates Id-1.5. The method of claim 1 wherein the delivery vehicle is an adenoviral,adeno-associated viral, lentis viral or retroviral vector, a cationicliposome, polycationic polymer or polyplex, a pharmaceuticallyacceptable composition, or a device which facilitates a delivery of suchdelivery vehicle.
 6. The method of claim 1 wherein said cancer isprostate cancer.
 7. expression The method of claim 4 wherein themolecule that modulates Id-1 expression is a peptide, pharmaceuticalcomposition or an organic compound.
 8. The method of claim 7 wherein themolecule that modulates Id-1 expression is an organic compound.
 9. Themethod of claim 5 wherein the delivery vehicle is a pharmaceuticallyacceptable composition.
 10. The method of claim 1 wherein saiddelivering step is carried out intravenously, orally or by injection.